Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NiBladder 2: SHR-1501 plus BCG vs placebo plus BCG in high-risk papillary NMIBC (BCG-naïve)
CTR20262829Phase 3Active
- Sponsor
- Suzhou Shengdiya Biopharmaceuticals
- Start
- Aug 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of SHR-1501 in bladder cancer, sponsored by Suzhou Shengdiya Biopharmaceuticals. Started Aug 2026; status: active.
02
Drugs
SHR-1501
03
Conditions
bladder cancer
Beyond the preview
Go deeper on CTR20262829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262829.